AU2002328945A1 - Methods for improved treatment of cancer with irinotecan based on mrp1 - Google Patents

Methods for improved treatment of cancer with irinotecan based on mrp1

Info

Publication number
AU2002328945A1
AU2002328945A1 AU2002328945A AU2002328945A AU2002328945A1 AU 2002328945 A1 AU2002328945 A1 AU 2002328945A1 AU 2002328945 A AU2002328945 A AU 2002328945A AU 2002328945 A AU2002328945 A AU 2002328945A AU 2002328945 A1 AU2002328945 A1 AU 2002328945A1
Authority
AU
Australia
Prior art keywords
mrp1
cancer
methods
improved treatment
irinotecan based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002328945A
Other languages
English (en)
Inventor
Gunther Heinrich
Reinhold Kerb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epidauros Biotechnologie AG
Original Assignee
Epidauros Biotechnologie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epidauros Biotechnologie AG filed Critical Epidauros Biotechnologie AG
Publication of AU2002328945A1 publication Critical patent/AU2002328945A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002328945A 2001-07-23 2002-07-23 Methods for improved treatment of cancer with irinotecan based on mrp1 Abandoned AU2002328945A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01117608 2001-07-23
EP01117608.8 2001-07-23
EP02011710.7 2002-05-24
EP02011710 2002-05-24
PCT/EP2002/008200 WO2003013533A2 (en) 2001-07-23 2002-07-23 Methods for improved treatment of cancer with irinotecan based on mrp1

Publications (1)

Publication Number Publication Date
AU2002328945A1 true AU2002328945A1 (en) 2003-02-24

Family

ID=26076655

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2002328945A Abandoned AU2002328945A1 (en) 2001-07-23 2002-07-23 Methods for improved treatment of cancer with irinotecan based on mrp1
AU2002331290A Abandoned AU2002331290A1 (en) 2001-07-23 2002-07-23 Methods for the treatment of cancer with irinotecan based on cyp3a5
AU2002328952A Abandoned AU2002328952A1 (en) 2001-07-23 2002-07-23 Irinotecan for treatment of cancer
AU2002328950A Abandoned AU2002328950A1 (en) 2001-07-23 2002-07-23 Methods for treatment of cancer using irinotecan based on ugt1a1
AU2002328953A Abandoned AU2002328953A1 (en) 2001-07-23 2002-07-23 Use of irinotecan for improved treatment of cancer based on mdr1

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2002331290A Abandoned AU2002331290A1 (en) 2001-07-23 2002-07-23 Methods for the treatment of cancer with irinotecan based on cyp3a5
AU2002328952A Abandoned AU2002328952A1 (en) 2001-07-23 2002-07-23 Irinotecan for treatment of cancer
AU2002328950A Abandoned AU2002328950A1 (en) 2001-07-23 2002-07-23 Methods for treatment of cancer using irinotecan based on ugt1a1
AU2002328953A Abandoned AU2002328953A1 (en) 2001-07-23 2002-07-23 Use of irinotecan for improved treatment of cancer based on mdr1

Country Status (6)

Country Link
US (1) US20050032724A1 (https=)
EP (5) EP1408972A2 (https=)
JP (5) JP2005504759A (https=)
AU (5) AU2002328945A1 (https=)
CA (5) CA2454640A1 (https=)
WO (5) WO2003013534A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4096037B2 (ja) * 2002-08-12 2008-06-04 国立大学法人滋賀医科大学 グルクロン酸転移酵素遺伝子の変異解析による薬剤代謝活性の予測方法
US7108992B2 (en) 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
US6916627B2 (en) 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
JP2006526412A (ja) 2003-05-30 2006-11-24 ユニバーシティ オブ シカゴ イリノテカン毒性を推定する方法および組成物
JPWO2005028645A1 (ja) * 2003-09-24 2007-11-15 株式会社産学連携機構九州 ＭＤＲ１遺伝子の５’制御領域におけるＳＮＰｓ
BRPI0415079A (pt) * 2003-10-06 2006-12-12 Novartis Ag biomarcadores para prognóstico de diarréia induzida por droga
JP2005245362A (ja) * 2004-03-05 2005-09-15 Kyowa Medex Co Ltd 肺癌および頭頸部癌の発症危険率を予測する方法
NZ550430A (en) * 2004-04-27 2009-06-26 Wellstat Biologics Corp Cancer treatment using viruses and camptothecins
WO2006009805A2 (en) * 2004-06-18 2006-01-26 Genentech, Inc. Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors
WO2006076288A2 (en) * 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
JP2007060967A (ja) * 2005-08-30 2007-03-15 Tokyo Institute Of Technology 遺伝子多型の検出方法および薬物のスクリーニング方法
JP2009515524A (ja) * 2005-11-10 2009-04-16 アメリカ合衆国 Ａｂｃｂ１多型バリアントスクリーニング、診断及び処置のための物質及び方法
EP2463365B1 (en) 2006-11-30 2013-09-18 ARKRAY, Inc. Probes for detection of UGT1A1 gene, reagent for detection of UGT1A1 gene comprising the same, and uses thereof
EP2448406B1 (en) * 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
WO2011031974A1 (en) * 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
AU2011223883B2 (en) 2010-03-01 2015-10-08 Cavion, Inc. Cancer diagnosis and imaging
JP2011250726A (ja) * 2010-06-01 2011-12-15 Toyo Kohan Co Ltd イリノテカンの副作用の発生危険度を判定する方法及びそのためのキット
AU2011281982B2 (en) 2010-07-20 2015-12-17 Bavarian Nordic A/S Method for harvesting expression products
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
KR102271848B1 (ko) * 2013-11-01 2021-07-01 피트니 파마슈티컬스 피티와이 리미티드 암 치료용 약학적 배합물
ES2843829T3 (es) * 2014-09-26 2021-07-20 Hi Stem Ggmbh Im Deutschen Krebsforschungszentrum Dkfz Nuevos métodos para la subtipificación y el tratamiento del cáncer
JP2016088919A (ja) * 2014-11-11 2016-05-23 国立研究開発法人産業技術総合研究所 イベルメクチン又はミルベマイシンｄを有効成分として含む抗癌剤
CN107208163B (zh) 2015-02-17 2021-01-08 国立大学法人山口大学 辅助对伊立替康副作用的发生风险的预测的方法
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
EP3337467B1 (en) 2015-08-20 2020-12-09 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
MX385425B (es) 2015-08-21 2025-03-18 Ipsen Biopharm Ltd Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico.
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
CN109939115B (zh) * 2019-05-06 2021-11-02 河南中医药大学 一种治疗放射性直肠炎的复方栓剂
US20230310478A1 (en) * 2020-09-02 2023-10-05 Ann And Robert H. Lurie Children's Hospital Of Chicago Methods and compositions for the treatment of pulmonary hypertension and cancer
CN114224875B (zh) * 2021-11-04 2023-08-11 中南大学湘雅医院 醇类化合物的新用途及抗肿瘤药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280855A1 (en) * 1997-02-27 1998-09-03 Pharmacia & Upjohn Company Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea
BR9916536A (pt) * 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
CA2295429A1 (en) * 2000-01-06 2001-07-06 Michael Michael Treatment or prevention of diarrhea
EP1251850B1 (en) * 2000-01-26 2006-06-21 Schering Corporation Use of a combination preparation in cancer therapy
WO2001087306A2 (en) * 2000-05-15 2001-11-22 Celgene Corp. Compositions and methods for the treatment of colorectal cancer
US20020169141A1 (en) * 2000-10-06 2002-11-14 Christophe Martin Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same

Also Published As

Publication number Publication date
JP2005504759A (ja) 2005-02-17
EP1408975A2 (en) 2004-04-21
JP2005505526A (ja) 2005-02-24
WO2003013534A3 (en) 2003-10-09
JP2005506971A (ja) 2005-03-10
WO2003013537A2 (en) 2003-02-20
CA2454643A1 (en) 2003-02-20
WO2003013536A2 (en) 2003-02-20
AU2002331290A1 (en) 2003-02-24
WO2003013535A9 (en) 2004-04-29
EP1408972A2 (en) 2004-04-21
WO2003013533A3 (en) 2003-10-09
EP1408974A2 (en) 2004-04-21
US20050032724A1 (en) 2005-02-10
AU2002328950A1 (en) 2003-02-24
EP1438050A2 (en) 2004-07-21
CA2454640A1 (en) 2003-02-20
CA2454627A1 (en) 2003-02-20
CA2454648A1 (en) 2003-02-20
WO2003013533A2 (en) 2003-02-20
WO2003013536A3 (en) 2003-12-18
WO2003013534A2 (en) 2003-02-20
WO2003013537A9 (en) 2004-04-29
AU2002328953A1 (en) 2003-02-24
WO2003013537A3 (en) 2003-09-25
WO2003013536A9 (en) 2004-04-29
WO2003013535A2 (en) 2003-02-20
EP1408973A2 (en) 2004-04-21
WO2003013533A9 (en) 2004-04-29
WO2003013535A3 (en) 2003-09-25
JP2005501840A (ja) 2005-01-20
WO2003013534A9 (en) 2004-04-29
AU2002328952A1 (en) 2003-02-24
JP2005508312A (ja) 2005-03-31
CA2454637A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
AU2002328945A1 (en) Methods for improved treatment of cancer with irinotecan based on mrp1
AU2002348135A1 (en) Methods for the treatment of addiction
AU2003226301A1 (en) Method of treating cancer
AU2002257936A1 (en) Methods of well treatment
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2003256847A1 (en) Method of treating cancer
AU2002303283A1 (en) Methods for treating drug addiction
EP1572093A3 (en) Improved treatment of cancer with glutamine
AU2002308522A1 (en) Methods for inhibiting tumor cell proliferation
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
AU2002308642A1 (en) Methods for treating cancer
AU2003223538A1 (en) Methods for the treatment of cancer
GB2389532C (en) The method of treating cancer
AU2003280558A1 (en) Method for treatment of cancer
AU2003231803A1 (en) Treatment of cancer with mefloquire
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AUPR963401A0 (en) Methods for the enhancement of complex peaks
AU2004281077A1 (en) Methods and agents for the treatment of cancer
AU2002305138A1 (en) Methods and materials for cancer treatment
AUPS165902A0 (en) Methods of treating brca associated disorder
AU2003272972A1 (en) Method of treatment for cancer
IL160242A0 (en) Methods for the treatment and prognosis of leukemia and other cancer types
AU2003272973A1 (en) Method for treatment of cancer
AU2003244633A1 (en) Methods for the treatment of sinusitis
AU2003905726A0 (en) Methods and agents for the treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase